MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, filing under ticker HLXA, is a clinical-stage biopharmaceutical company focused on inflammatory diseases, including hidradenitis suppurativa and psoriatic arthritis, with a nanobody-based therapeutic platform. The company reached the public markets through a business combination with Helix Acquisition Corp, a healthcare-sector blank-check vehicle that completed its IPO in 2021 under sponsorship from Helix Acquisition Holdings LLC. The de-SPAC transaction closed in 2022, establishing MoonLake as a reporting public company. On May 11, 2026, the company filed an 8-K current report with the SEC, continuing its active disclosure obligations. For full filing history, sponsor profiles, and SPAC deal data on HLXA and thousands of other transactions, sign up at SpacDesk.